- In March 2024, Endo International plc announced the expansion of its deoxycholic acid product, Qwo, into select international markets following successful domestic performance in the U.S. The company aims to capitalize on growing global demand for non-invasive fat reduction therapies. This strategic move highlights Endo’s commitment to scaling its aesthetic medicine portfolio and strengthening its presence in the global obesity drug landscape
- In February 2024, Revance Therapeutics, Inc. unveiled positive results from a Phase IV post-marketing study assessing the long-term safety and efficacy of its injectable deoxycholic acid product. The data demonstrated sustained submental fat reduction and high patient satisfaction rates over a 12-month period. These findings are expected to support expanded clinical usage and regulatory filings in new territories, emphasizing Revance's dedication to evidence-backed innovation in aesthetic medicine
- In November 2023, Allergan Aesthetics, an AbbVie company, received regulatory approval in Brazil for the expanded use of Kybella (deoxycholic acid) for small-area fat reduction, including underarm and jawline contouring. This approval aligns with Allergan's global expansion strategy and rising consumer interest in localized fat reduction. The development reaffirms the brand’s leadership in the injectable aesthetic treatment segment and its focus on meeting diverse patient needs
- In October 2023, Hugel, Inc., a South Korea-based aesthetics and biopharma company, entered into a licensing agreement with a European distributor to commercialize its deoxycholic acid-based fat reduction solution across Germany, France, and Spain. The deal represents Hugel’s entry into the European obesity aesthetic drug market and showcases the growing globalization of East Asian pharmaceutical innovations
- In August 2023, Evolus, Inc. initiated a research partnership with academic dermatology centers in the U.S. and Canada to evaluate the integration of deoxycholic acid injectables into multi-modality body contouring regimens. The initiative reflects the industry's growing focus on personalized aesthetic therapies and underlines Evolus’ commitment to advancing clinical outcomes and expanding treatment indications for obesity-related aesthetic product
